Recombinant Human Erythropoietin Therapy in Children on Dialysis

Abstract

The addition of recombinant human erythropoietin (rHuEPO) to the therapeutic regimen for children with chronic renal failure (CRF) is one of the most important improvements in care in the last 20 years. Anemia had played an important role in the morbidity of chronic dialysis treatment. Before the availability of rHuEPO, repeated erythrocyte transfusions provided incomplete treatment and had significant long-term sequelae. Recombinant erythropoietin treatment resulted in the amelioration of anemia and marked reduction in transfusions. Additional benefits of the correction of anemia with rHuEPO include improvements in exercise tolerance and regression of ventricular hypertrophy. Many rHuEPO-treated patients have had subjective increases in appetite, but there has been no consistent improvement in dietary intake or anthropometric measures. Correction of anemia with rHuEPO has not been shown to improve the growth of children with CRF receiving dialysis. The most significant adverse effects of rHuEPO are the development of iron deficiency and the exacerbation or development de novo of hypertension. RHuEPO treatment has been shown to treat the anemia of CRF in children safely and effectively. In most cases, putative inhibitors of erythropoiesis and blood loss can be overcome. Many of the symptoms previously ascribed to "uremia" have improved with correction of anemia. The full implications of treatment of anemia with rHuEPO will be clearer when the health outcomes for children who never become severely anemic or require transfusions are more completely studied.